In this double-blind , placebo-controlled , phase @ trial , patients with viable intraparenchymal neurocysticercosis were randomly assigned to receive @ days of combined albendazole ( @ mg/kg per day ) plus praziquantel ( @ mg/kg per day ) , standard albendazole ( @ mg/kg per day ) , or increased dose albendazole ( @ mg/kg per day ) .